The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
Wu J, Zhou L, Liu J, et al. Critical Care 2013;17:R8.
What it found
28-day death rates were 26.0% with thymosin alpha-1 and 35.0% in controls (relative risk 0.74, 95% CI 0.54 to 1.02; P = 0.062 unstratified, 0.049 by log-rank). The immune marker mHLA-DR improved more on days 3 and 7. No serious drug-related adverse events were recorded.
Limitations
Single-blind, no placebo, six centres in China. The mortality result was borderline. A later, larger double-blind trial did not confirm a benefit.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.